B & T Capital Management DBA Alpha Capital Management Has $4.36 Million Stock Position in Amgen Inc. (NASDAQ:AMGN)

B & T Capital Management DBA Alpha Capital Management boosted its holdings in shares of Amgen Inc. (NASDAQ:AMGN) by 1.0% during the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 13,534 shares of the medical research company’s stock after buying an additional 129 shares during the period. B & T Capital Management DBA Alpha Capital Management’s holdings in Amgen were worth $4,361,000 as of its most recent filing with the Securities and Exchange Commission.

Several other large investors have also recently bought and sold shares of the business. GEM Asset Management LLC raised its position in Amgen by 14.2% during the third quarter. GEM Asset Management LLC now owns 749 shares of the medical research company’s stock valued at $238,000 after buying an additional 93 shares during the period. Modus Advisors LLC grew its stake in Amgen by 3.6% in the third quarter. Modus Advisors LLC now owns 7,374 shares of the medical research company’s stock valued at $2,376,000 after purchasing an additional 259 shares in the last quarter. Steigerwald Gordon & Koch Inc. grew its stake in Amgen by 2.1% in the third quarter. Steigerwald Gordon & Koch Inc. now owns 70,016 shares of the medical research company’s stock valued at $22,560,000 after purchasing an additional 1,473 shares in the last quarter. Matrix Trust Co purchased a new position in Amgen in the third quarter valued at about $36,000. Finally, Cadinha & Co. LLC grew its stake in Amgen by 0.6% in the third quarter. Cadinha & Co. LLC now owns 5,209 shares of the medical research company’s stock valued at $1,678,000 after purchasing an additional 32 shares in the last quarter. 76.50% of the stock is owned by institutional investors and hedge funds.

Amgen Stock Performance

NASDAQ:AMGN traded down $0.78 during mid-day trading on Thursday, hitting $321.63. 471,146 shares of the company’s stock traded hands, compared to its average volume of 2,467,382. The firm has a 50 day moving average of $326.46 and a two-hundred day moving average of $310.14. Amgen Inc. has a 12 month low of $249.70 and a 12 month high of $346.85. The firm has a market capitalization of $172.53 billion, a price-to-earnings ratio of 46.06, a price-to-earnings-growth ratio of 2.98 and a beta of 0.61. The company has a current ratio of 1.26, a quick ratio of 0.89 and a debt-to-equity ratio of 9.64.

Amgen (NASDAQ:AMGN) last posted its quarterly earnings results on Tuesday, August 6th. The medical research company reported $4.97 EPS for the quarter, missing the consensus estimate of $5.01 by ($0.04). The firm had revenue of $8.39 billion during the quarter, compared to analyst estimates of $8.35 billion. Amgen had a net margin of 10.12% and a return on equity of 161.72%. The company’s revenue was up 20.1% on a year-over-year basis. During the same period last year, the company earned $5.00 EPS. On average, equities analysts forecast that Amgen Inc. will post 19.49 earnings per share for the current fiscal year.

Amgen Announces Dividend

The company also recently declared a quarterly dividend, which was paid on Tuesday, August 6th. Shareholders of record on Friday, August 16th were issued a $2.25 dividend. The ex-dividend date of this dividend was Friday, August 16th. This represents a $9.00 annualized dividend and a yield of 2.80%. Amgen’s dividend payout ratio (DPR) is 128.57%.

Analyst Ratings Changes

AMGN has been the topic of a number of recent research reports. Robert W. Baird restated an “underperform” rating and issued a $215.00 target price on shares of Amgen in a research note on Wednesday, September 25th. Barclays boosted their target price on Amgen from $300.00 to $315.00 and gave the company an “equal weight” rating in a research note on Monday. TD Cowen boosted their target price on Amgen from $360.00 to $381.00 and gave the company a “buy” rating in a research note on Wednesday, August 7th. Deutsche Bank Aktiengesellschaft restated a “hold” rating and issued a $305.00 target price (down previously from $310.00) on shares of Amgen in a research note on Wednesday, August 7th. Finally, Bank of America upped their price target on Amgen from $325.00 to $330.00 and gave the stock a “neutral” rating in a research note on Wednesday, August 7th. One analyst has rated the stock with a sell rating, eleven have assigned a hold rating, twelve have given a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat, Amgen presently has an average rating of “Moderate Buy” and a consensus price target of $326.30.

Amgen Profile

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.